Good MorningEquities rebounded on Wednesday despite another round of bearish news that included the PPI data and earnings from JPMorgan Chase. The PPI data shows producer prices accelerating more than expected to the fastest pace on record. This data is sure to lead to another increase in the CPI data next month or later in the year which brings us to the JPMorgan Chase report. The company says it is bracing for increased economic risks and we think it is a wise decision.
The impacts of Russia's invasion of Ukraine are only beginning to show up in the data and results and those impacts are not good. Rising fuel costs and disruptions to trade are only the tip of the iceberg and threaten to throw the global economy into a recession. The next hurdle for the market will come today with an earnings report from at least half a dozen of the world's largest financial institutions. If they report more of what JPMorgan Chase reported the market sell-off could resume with increased vigor. Featured: Why Every Advisor Pushes the Same Investment Strategy (Ad) 
|
Industrials | |
Solar tracking systems provider Array Technologies (NASDAQ: ARRY) stock has fallen below its pandemic lows despite improving business. The Company manufactures and supplies single-axis solar tracking systems that enable the optimal positioning of a solar array to increase clean and renewable energ... Read the Full Story |
|
From Our Partners | | President Trump says America is building wealth again, and the U.S. Treasury calls the economy under his administration strong.
But markets still fluctuate, companies still miss expectations, and a major loss late in your career can be harder to recover from than one at age 40.
Physical gold offers protection that does not depend on market momentum, corporate earnings, or consumer spending. | | Download the free 2026 Wealth Preservation Guide to protect your retirement savings |
|
Technology | |
Robotic process automation (RPA) platform provider UiPath (NASDAQ: PATH) stock has been getting crushed to new lows ever since hitting highs of $90 nearly a year ago. The Company is a leader in RPA, which enables companies to better automate their repetitive processes. It’s both software rob... Read the Full Story |
|
Technology | |
These 3 S&P Stocks Could Be Bargains
One of the most common pieces of advice when it comes to investing is to “buy low and sell high”. While this definitely sounds good on paper, finding the right opportunities in the market at the right time is easier said than done. That’s... Read the Full Story |
|
From Our Partners | | Vincere licenses institutional-grade futures algorithms directly to individual investors — no nine-figure minimums, no PhD team required.
Your capital never leaves your U.S.-regulated brokerage or IRA. No leverage, no overnight positions, and the worst month in six years was -2.58 percent. No management fees or profit cuts — every dollar earned stays in your account.
Built by former hedge-fund quant researchers, Chicago-based and SEC-compliant, with a public team you can verify. | | See how the algorithm works inside your own brokerage account |
|
Industrials | |
These stocks combine solid fundamentals with a stock price near its 52-week low
Some of you with children may participate in an Easter Egg hunt this weekend. If that’s the case for you, I hope your kids come home with lots of little treasures.
That got me thinking. With the red-hot CPI ... Read the Full Story |
|
Consumer Discretionary | |
Pricing Power Drives Lululemon Higher
Lululemon Athletica (NASDAQ: LULU) impressed the market when it reported fiscal Q4 earnings at the end of March. The company beat on the bottom line and raised its guidance as demand and pricing combined to boost the earnings results. In the eyes of Bank of... Read the Full Story |
|
From Our Partners | | A 60-minute morning window is catching traders' attention for one reason: it doesn't depend on market direction.
Place a quick trade before 10 am, then step away. Sixty minutes later, the setup has already done its work.
The strategy targets a 50 percent return potential on a $1,000 stake, though results vary and some trades won't work out. | | Discover how to apply this 60 minute trading window today |
|
Technology | |
Infosys Growth Is Priced In
Infosys (NYSE: INFY) is still growing, it’s still making profits, and it’s still on track to pay a higher dividend than it did last year but the market for the stock has peaked. This is because the growth is more than priced in and sell-side support is wan... Read the Full Story |
|
Technology | | It’s been a rocky few months for shares of Nvidia (NASDAQ: NVDA) since they hit an all-time high last November. They got caught up in the general market weakness at the start of the year as investors’ sentiment swung to risk-off. Then rising inflation prints and higher interest rates, co... Read the Full Story |
|
Markets | |
These 3 Steel Stocks Are Solid Picks
Metals and mining stocks have been a major bright spot in the stock market this year, and with some analysts anticipating a commodity super-cycle ahead, there could still be a lot more upside for investors that have positions in the strongest companies in the ... Read the Full Story |
|
Markets | |
Supply Chain Disruption Sucks Wind From Bed Bath & Beyond Recovery
Bed Bath & Beyond (NASDAQ: BBBY) had a horrible quarter impacted by supply chain disruptions that have its inventory in transit or sitting in port. As bad as the news is for Bed Bath & Beyond investors the repercussio... Read the Full Story |
|
Industrials | |
Fast-Acting Fastenal Execs Grow Business And Widen Margin
Fastenal (NASDAQ: FAST) has been on our watchlist for quite some time due to its positioning in the industrial, housing, and retail markets. The company manufacturers and markets a wide range of tools, safety products, and fasteners (nail... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. | | View Today's Stock Pick |
|
